Advertisement
Advertisement

Susan Haigney

UBM Americas

Susan Haigney is lead editor of Pharmaceutical Technology and Pharmaceutical Technology Europe.

Articles

Advertisement

USP Changes Heparin Labeling Requirement

November 05, 2012

USP revises labeling requirements for Heparin.

FDA Assesses Goals due to Hurricane Sandy

November 04, 2012

FDA has pushed back goals in relation to the Prescription Drug User Fee Act (PDUFA), the Biosimilar User Fee Act (BsUFA), and Medical Device User Fee Act (MDUFA) as a result of the closing of agency offices during Hurricane Sandy.

Eli Lilly Chairman Stresses the Importance of Biopharmaceutical Innovation on the Economy

October 17, 2012

The recent presidential and vice-presidential debates have highlighted the need for strategies for economic growth in the US, including the roles innovation and trade play in stimulating the US economy.

Is FDA putting your company’s confidential data at risk?

September 27, 2012

An upcoming PharmTech Viewpoint article (Check out PharmTech’s October issue) raises that very question.

Is FDA putting your company’s confidential data at risk?

September 27, 2012

An upcoming PharmTech Viewpoint article (Check out PharmTech’s October issue) raises that very question.

Advertisement

USP Updates Heparin Sodium Monograph

September 13, 2012

In 2008, adverse affects and deaths linked to Baxter’s blood thinner drug heparin revealed contamination in the heparin supply chain originating from an API manufacturer in China. FDA identified oversulfated chondroitin sulfate (OSCS) in the contaminated heparin.

Advertisement
Advertisement
Advertisement
x